The vaccine was designed by Pfizer Pharmaceutical Company to stimulate the immune system to fight against infections caused by the bacteria Staphylococcus aureus.
The infection is particularly concerning in patients undergoing spinal surgery, Vik Patel, MD, professor and chief of orthopedic spine surgery at UCH, told CBS Denver.
“It can lead to chronic infection. It can require additional surgeries to clean it up to get rid of the infection,” said Dr. Patel. “It can be deadly, too.”
The vaccine trial is expected to end in 2017.
More articles on staph:
Researchers identify effective new MRSA decolonization protocol
MRSA detection technology earns first patent
Genome researchers dive deep to differentiate dangerous Staph
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.